STEALTH BIOTHERAPEUTICS CORP (MITO) Stock Price, Quote, News and Overview
NASDAQ:MITO - Nasdaq - US85789A1051 - ADR - Currency: USD
MITO Quote, Performance and Key Statistics
NASDAQ:MITO (11/15/2022, 8:00:01 PM)
0.32
0 (-1.36%)
The current stock price of MITO is 0.32 USD. In the past month the price increased by 0.95%. In the past year, price decreased by -65.96%.
MITO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About MITO
Company Profile
Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company is headquartered in George Town, Grand Cayman and currently employs 38 full-time employees. The company went IPO on 2019-02-15. The firm is focused on the discovery, development and commercialization of therapies for diseases involving mitochondrial dysfunction. Its clinical product candidate, elamipretide, is a small peptide that targets and binds reversibly to cardiolipin, a structural element of mitochondria, stabilizing the inner mitochondrial membrane under conditions of oxidative stress. This mechanism of action has shown potential clinical benefit in both rare genetic and common age-related ophthalmic and cardiac diseases entailing mitochondrial dysfunction. The firm's second clinical product candidate include SBT-272, for rare neurological diseases involving mitochondrial dysfunction, with a preliminary focus on amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Its clinical product candidate also includes SBT-550 series for rare neurological indications, including Friedreich’s ataxia (FRDA).
Company Info
STEALTH BIOTHERAPEUTICS CORP
190 Elgin Avenue, George Town
GEORGE TOWN GRAND CAYMAN KY1-9005 KY
CEO: Irene (Reenie) McCarthy
Employees: 38
Company Website: https://www.stealthbt.com/
Phone: 6176006888.0
STEALTH BIOTHERAPEUTICS CORP / MITO FAQ
What is the stock price of STEALTH BIOTHERAPEUTICS CORP today?
The current stock price of MITO is 0.32 USD. The price decreased by -1.36% in the last trading session.
What is the ticker symbol for STEALTH BIOTHERAPEUTICS CORP stock?
The exchange symbol of STEALTH BIOTHERAPEUTICS CORP is MITO and it is listed on the Nasdaq exchange.
On which exchange is MITO stock listed?
MITO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for STEALTH BIOTHERAPEUTICS CORP stock?
7 analysts have analysed MITO and the average price target is 1.81 USD. This implies a price increase of 465.78% is expected in the next year compared to the current price of 0.32. Check the STEALTH BIOTHERAPEUTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is STEALTH BIOTHERAPEUTICS CORP worth?
STEALTH BIOTHERAPEUTICS CORP (MITO) has a market capitalization of 23.54M USD. This makes MITO a Nano Cap stock.
How many employees does STEALTH BIOTHERAPEUTICS CORP have?
STEALTH BIOTHERAPEUTICS CORP (MITO) currently has 38 employees.
What are the support and resistance levels for STEALTH BIOTHERAPEUTICS CORP (MITO) stock?
STEALTH BIOTHERAPEUTICS CORP (MITO) has a support level at 0.32 and a resistance level at 0.33. Check the full technical report for a detailed analysis of MITO support and resistance levels.
Should I buy STEALTH BIOTHERAPEUTICS CORP (MITO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MITO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MITO, evaluating the profitability, health, valuation and growth aspects
- STEALTH BIOTHERAPEUTICS CORP (MITO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- STEALTH BIOTHERAPEUTICS CORP (MITO) Sales and EPS estimates to see what analysts future expectations are.
- STEALTH BIOTHERAPEUTICS CORP (MITO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- STEALTH BIOTHERAPEUTICS CORP (MITO) Insider and Institutional Ownership to learn about the owners and their transactions.
- STEALTH BIOTHERAPEUTICS CORP (MITO) Stock Chart to make your own analysis
- STEALTH BIOTHERAPEUTICS CORP (MITO) Latest news and press-releases to stay up to date.
Does STEALTH BIOTHERAPEUTICS CORP (MITO) stock pay dividends?
MITO does not pay a dividend.
What is the Price/Earnings (PE) ratio of STEALTH BIOTHERAPEUTICS CORP (MITO)?
STEALTH BIOTHERAPEUTICS CORP (MITO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.08).
MITO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MITO. When comparing the yearly performance of all stocks, MITO is a bad performer in the overall market: 78.6% of all stocks are doing better.
MITO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MITO. MITO may be in some trouble as it scores bad on both profitability and health.
MITO Financial Highlights
Over the last trailing twelve months MITO reported a non-GAAP Earnings per Share(EPS) of -0.08.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -143.5% | ||
| ROE | N/A | ||
| Debt/Equity | -0.26 |
MITO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to MITO. The Buy consensus is the average rating of analysts ratings from 7 analysts.